CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion

Cancer Research

Volumn 69, Issue 15, 2009, Pages 6331-6338

  Nesbeth, Yolanda ^a   Scarlett, Uciane ^a   Cubillos Ruiz, Juan ^a   Martinez, Diana ^a   Engle, Xavier ^a   Turk, Mary Jo ^a   Conejo Garcia, Jose R ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b HB 7556 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; PERFORIN; RANTES; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DENDRITIC CELL; IMMUNOSTIMULATION; INTERFERON PRODUCTION; LYMPHOCYTE TRANSFER; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD11C; CHEMOKINE CCL5; DENDRITIC CELLS; FEMALE; GRANZYMES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NIH 3T3 CELLS; OVARIAN NEOPLASMS; T-LYMPHOCYTES;

EID: 68049118835     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4329     Document Type: Article

References (30)

1. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308.
2. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-854
3. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-129
4. + T cells against NY-ESO-1. N Engl J Med 2008;358:2698-2703
5. + T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006;211:214-224
6. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005;115:1616-1626 (Pubitemid 40814670)
7. + T cells. J Exp Med 2003;198:569-580
8. Coukos G, Conejo-Garcia JR, Roden RB, Wu TC. Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther 2005;5:1193-1210
9. Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase- 5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006;203:2691-2702 (Pubitemid 44833345)
10. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008;118:1991-2001.
11. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using genemodified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-6115
12. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
13. Conejo-Garcia JR, Benencia F, Courreges MC, et al. Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells. Cancer Res 2004;64:2175-2182 (Pubitemid 38339470)
14. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213 (Pubitemid 36077915)
15. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-18543
16. + T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007;104:3360-3365
17. Ramakrishna V, Ross MM, Petersson M, et al. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 2003;15:751-763 (Pubitemid 36675806)
18. Yen MJ, Hsu CY, Mao TL, et al. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 2006;12:827-831
19. Odunsi K, Jungbluth AA, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003;63:6076-6083 (Pubitemid 37187513)
20. Hasegawa K, Koizumi F, Noguchi Y, et al. SSX expression in gynecological cancers and antibody response in patients. Cancer Immun 2004;4:16.
21. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007;67:9518-9527 (Pubitemid 47535942)
22. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloidderived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008;68:5439-5449
23. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949 (Pubitemid 39273735)
24. Huarte E, Cubillos-Ruiz JR, Nesbeth YC, et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008;68:7684-7691
25. Coukos G, Conejo-Garcia JR, Buckanovich R, Benencia F. Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer. Adv Exp Med Biol 2007;590:185-193
26. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999;223:77-92. (Pubitemid 29096240)
27. Conejo-Garcia JR, Benencia F, Courreges MC, et al. Tumor-infiltrating dendritic cell precursors recruited by a h-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004;10:950-958 (Pubitemid 39273736)
28. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005;202:907-912 (Pubitemid 41396891)
29. Barber A, Zhang T, Sentman CL. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J Immunol 2008;180:72-8.
30. + T cells. Gene Ther 2007;14:921-929